4D Molecular Therapeutics Inc (FDMT)
24.18
-0.07
(-0.29%)
USD |
NASDAQ |
Apr 30, 14:13
4D Molecular Therapeutics Shareholders Equity (Quarterly): 307.83M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 307.83M |
| September 30, 2023 | 329.93M |
| June 30, 2023 | 325.14M |
| March 31, 2023 | 218.61M |
| December 31, 2022 | 231.34M |
| September 30, 2022 | 251.44M |
| June 30, 2022 | 272.52M |
| March 31, 2022 | 296.06M |
| December 31, 2021 | 319.11M |
| Date | Value |
|---|---|
| September 30, 2021 | 224.13M |
| June 30, 2021 | 240.65M |
| March 31, 2021 | 242.43M |
| December 31, 2020 | 256.39M |
| September 30, 2020 | 70.16M |
| December 31, 2019 | -72.97M |
| June 30, 2019 | -42.30M |
| December 31, 2018 | -27.59M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-72.97M
Minimum
Dec 2019
329.93M
Maximum
Sep 2023
216.90M
Average
246.94M
Median
Shareholders Equity (Quarterly) Benchmarks
| Catalent Inc | 3.687B |
| Cytokinetics Inc | -386.32M |
| Vertex Pharmaceuticals Inc | 17.58B |
| Karyopharm Therapeutics Inc | -136.21M |
| Minerva Neurosciences Inc | -28.46M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 339.89M |
| Total Liabilities (Quarterly) | 32.06M |
| Current Ratio | 15.65 |